Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma

This publication has 15 references indexed in Scilit:

• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• Lysis of primary hepatic tumours by lymphokine activated killer cells.
  Gut, 1987
• High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings
  JAMA, 1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report
  International Journal of Cancer, 1984
• Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells
  Cancer, 1984
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982
• Interleukin‐2 Dependent Culture of Cytolytic T Cell Lines
  Immunological Reviews, 1981
• T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity
  The Journal of Immunology, 1978